Global Pharma Companies Rush into Nephrology, Poised to Reshape Treatment Landscape

　　【Pharmaceutical Network Industry DynamicsRecently, Boehringer Ingelheim (BI) announced a collaboration worth up to $448 million to jointly develop a preclinical oral drug for chronic kidney disease (CKD) with Rectify. The core of this collaboration lies in Rectify's Positive Functional Modulators (PFMs) platform, which aims to address membrane protein dysfunction and develop novel small-molecule drugs that enhance the function of the ABCC6 protein, potentially offering a fundamental solution to pathological calcification in chronic kidney disease.
 

It is reported that Boehringer Ingelheim has significant advantages in the cardiovascular-renal-metabolic field and has launched several classic drugs. This collaboration not only highlights the value of the Rectify technology platform but also represents another important strategic layout in the renal disease field.
 

In fact, the nephrology field has tremendous potential and is becoming a golden track that global pharmaceutical companies are rushing to develop. By 2025, many pharmaceutical companies have strategically positioned themselves in this area through external licensing and pipeline acquisitions.
 

By the end of December 2025, Hansoh Pharma and Hengrui Pharma reached an authorization cooperation agreement for the SHR6508 project. The total amount of this cooperation can reach 220 million RMB (30 million upfront payment + up to 190 million milestone payment + sales sharing). SHR6508 is a Phase III clinical new drug developed by Hengrui Pharma targeting secondary hyperparathyroidism (SHPT) in hemodialysis patients. Through this transaction, Hengrui Pharma can focus on core R&D, while Hansoh Pharma can leverage its commercialization capabilities in the nephrology and dialysis fields to accelerate product launch.
 

On December 18, CAMP4 Therapeutics announced that it had reached a strategic research, collaboration, and licensing agreement with GSK to jointly identify and develop antisense oligonucleotide (ASO) candidates targeting multiple gene targets associated with neurodegenerative and kidney diseases. CAMP4 will receive an upfront payment of $17.5 million (approximately 123 million RMB). Additionally, there is the potential to receive additional payments upon achieving certain R&D and commercial milestones, as well as tiered royalties on future product sales.
 

On December 12, TaiGen Biopharmaceutical announced an exclusive pipeline out-licensing collaboration with Insilico Medicine. According to the agreement terms, TaiGen Biopharmaceutical will obtain the exclusive rights for development, commercialization, and sublicensing of ISM4808 in Greater China—including mainland China, Hong Kong, Macao, and Taiwan—while Insilico Medicine will receive a return worth tens of millions of US dollars from this deal. ISM4808 is a drug used to treat anemia in patients with chronic kidney disease (CKD), and this collaboration injects new momentum into advancing the subsequent development and market promotion of the drug.
 

On December 1, Akebia Therapeutics announced the establishment of a rare kidney disease pipeline, with core assets including the acquired complement inhibitor AKB-097 and the existing sGC agonist Praliciguat.
 

　　……
 

This series of transactions is actually highlighting the huge potential in the field of nephrology. The industry believes that numerous pharmaceutical companies worldwide are increasing their investment in nephrology, which will accelerate the profound transformation of the industry from traditional symptomatic treatment to innovative approaches at the source, platform mergers and acquisitions, and specialized deep cultivation. In the coming years, as the pipelines from these strategic layouts gradually yield clinical data and are introduced to the market, the landscape of nephrology treatment is expected to undergo significant changes.
 

　　Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.